Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.

Zhitongcaijing · 1d ago
Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.